SFA Therapeutics offer a new approach to treating chronic inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease (IBD), Crohn's disease, psoriasis, hepatitis B, and certain types of cancer.

SFA Therapeutics offer a new approach to treating chronic inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease (IBD), Crohn’s disease, psoriasis, hepatitis B, and certain types of cancer. Our drugs are derived from natural substances identified at Temple University and enable a new platform for developing treatments potentially aimed at many inflammatory diseases currently afflicting patients; with safer treatments than current therapies. Our initial focus is in Psoriasis and Hepatitis B, NASH and Hepatocellular Carcinoma. Patents have been filed in these diseases, based on animal data in liver disease and on a small human trial ex-US in psoriasis. Additional patents are expected in a wide range of inflammatory diseases, including ophthalmic diseases, prenatal care and CAR-T (immuno-oncology).
Industry: Health
Status: Active

Contact Information

http://sfatherapeutics.com/

iraspector@sfatherapeutics.com

Dr. Ira Spector

CEO & Co-Founder

Dr. Mark Feitelson

CSO & co-founder

Dr. Alla Arzumanyan

CSO & co-founder